Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The primary objective of the proposed project is to decipher how extracellular vesicle (EV) biogenesis and its role in intercellular communication can be impaired as a consequence of defects in lysosomal function. Collectively these defects in EV biogenesis and function can contribute to the neuroinflammation observed in lysosomal storage diseases. Since EVs can cross the blood-brain barrier, their characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the secretion of EVs. Further, there will be differences in EV size, its cargo including lipids, RNA and proteins and their aggregates. In comparison to healthy controls, EVs isolated from patients with Gaucher disease (GD) and GBA1 carriers is hypothesized to show significant differences in terms of its characteristics and content, which can contribute to our understanding of the link between lysosomes and neurological disease.

Who May Be Eligible (Plain English)

Who May Qualify: - Age between 18-80yrs - Restricted to participants who are untreated, obligate carriers and healthy controls. - Participants with GD should have confirmed GD diagnosis, mutation confirmed for carriers and healthy controls confirmed to have no GBA1 mutation by gene sequencing. Who Should NOT Join This Trial: - Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions. - Exclude participants who are currently on therapy for their GD - Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age between 18-80yrs * Restricted to participants who are untreated, obligate carriers and healthy controls. * Participants with GD should have confirmed GD diagnosis, mutation confirmed for carriers and healthy controls confirmed to have no GBA1 mutation by gene sequencing. Exclusion Criteria: * Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions. * Exclude participants who are currently on therapy for their GD * Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.

Treatments Being Tested

OTHER

no intervention

no intervention, this is an observational study

Locations (1)

University of Minnesota
Minneapolis, Minnesota, United States